The antiphospholipid syndrome. Manifestation, diagnosis and therapy;Das antiphospholipid-syndrom. Klinische manifestation, diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 47, 2004, Pages 2547-2552

  Miesbach, Wolfgang ^a   Scharrer, I ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; FLUINDOSTATIN; HEPARIN; IMMUNOGLOBULIN; PHENPROCOUMON; RITUXIMAB; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CLINICAL FEATURE; HUMAN; LABORATORY DIAGNOSIS; NEUROLOGIC DISEASE; PATHOGENESIS; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; VEIN THROMBOSIS;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS;

EID: 9644252791     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835300     Document Type: Review

References (70)

1. Alarcón-Segovia D, Boffa MC, Branch W et al. Prophylaxis of the antiphospholipid syndrome: a consensus report Lupus 2003; 12: 499-503
2. Alarcón-Segpvia D, Pérez-Vázquez ME, Villa AR, Drenkard C, CabiedesJ. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-286.
3. Alliot C, Messouak D, Albert F. Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome. Am J Hematol 2001; 68: 215
4. Al-Saeed A et al. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994; 88: 845-848
5. al Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkhoff AV. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rneumatol 1997; 24: 1716-1718
6. The APASS writing Committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584
7. Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534
8. s Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207
9. Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR. Major histocompatibility complex assiociations with primary antiphospholipid syndrome. Arthrits Rheum 1992; 35: 124-125
10. Bentolila S, Fremeaux-Bacchi V, Weiss L, Blouin J, Kazatchkine MD, Piette JC. High frequency of C4 "null" alleles in primary antiphospholipid syndrome. Ann Med Interne 1996; 147: 115-116
11. Blank M, Faden D, Tincani A et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naïve mice. J Autoimmun 1994; 7: 441-455
12. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190
13. Carreno L, Monteagudo I, Lopez LF et al. Anticardiolipin antibodies in pediatric patients with human immunodeficiency virus. J Rheumatol 1994; 21: 1344-1346
14. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on systemic lupus erythematosus. Medicine 1999; 78: 167-175
15. Cervera R, Piette JC, Font J et al. Antiphospholipid Syndrome - Clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027
16. Chapman J, Rand JH, Brey RL et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12: 514-517
17. Cheng Y, Wong R, Soo Y et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836
18. Crowther MA, Ginsberg JS, Julian I et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138
19. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood 2001; 98: 1760-1764
20. Erkan D, Asherson RA, Espinosa G et al. Catastrophic antiphospholipid syndrome registry project group. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62: 530-533
21. Erkan D,Merill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome - effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466-1467
22. Fabris F, Steffan A et al. Specific antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-236
23. Facer CA, Agiostratidou G. High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodmm falciparum and in P.vivax malaria. Clin Exp Immunolol 1994; 95: 304-309
24. Ferrara DE, Liu X, Espinola RG et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthr Rheum 2003; 48: 3272-3279
25. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996; 100: 530-536
26. Font J, Jiménez S, Cervera R et al. Splenectomy for refractory Evan's syndrome associated with antiphospholipid antibodies: report of two cases. Ann Rheum Dis 2000; 59: 920-923
27. Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001; 47: 985-987
28. Galli M, Confurius P, Massau C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
29. Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994; 71: 571-575
30. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russel's viper venome time distinguish between prothrombin- and β2-glycoprotein-I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-623
31. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832
32. Gharayi AE, Harris EN, Asherson RA, Hughes GRV. Isotype distribution and phospholipid specifity in the antiphospholipid syndrome. Ann Rheum Dis 1987; 46: 1-6
33. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia or primary antiphospholipid syndrome. Br J Haematol 1997; 98: 873-879
34. Harris EN, Gharavi AE, Hedge U et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematology 1985; 59: 231-234
35. Jung F, Miesbach W, Scharrer I. Cardiac and cerebral manifestations of antiphospholipid syndrome. Z Kardiol 2002; 91: 650-658
36. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997; 54: 209-213
37. Karassa FB, Bijl M, Davies KA et al. Role of Fc-gamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48: 1930-1938
38. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997
39. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589
40. Lechner K, Pabinger-Fasching I. Lupus antikoagulant and thrombosis: a study of 25 cases and review of the literature. Hemostasis 1985; 15: 254-262
41. Levine SR, Brey RL, Sawaya KL et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995; 38: 119-124
42. Levine SR, Salowich-Palm L, Sawaya KL et al. IgG anticardiolipin antibody titer>40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28: 1660-1665
43. Matsuura H, Igarasha T, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 117-118
44. Mc Neil HD, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein 1 (apolipiprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
45. Merill JT. Rituximab in antiphospholipid syndrome. Curr Rheumatol Rep 2003; 5: 381-382
46. Meroni PL, Moia M, Derksen RHWM et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003; 12: 504-507
47. Miesbach W, Scharrer I, Asherson RA. Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation. Clin Rheum 2004; 23: 256-261
48. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994; 344: 452-464
49. Munoz-Rodriguez FJ, Font J et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999; 29: 182-190
50. Qgasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y. Anti beta 2 glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus 1996; 5: 587-592
51. Pasquier E, Amiral J, de Saint Martin L, Mottiert D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001; 86: 538-542
52. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909-913
53. Pengo V, Biasiolo A, Brocco T, Tonett S, Ruffatti A. Autoantibodies to phospholipid - binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-724
54. Petri M. Classification and epidemiology of the antiphospholipid syndrome. First edition (Hrsg). Amsterdam: Elsevier, In Asherson A, Cervera R, Piette JC, Shoenfeld Y, editors. The antiphospholipid syndrome II. 2002: 11-20
55. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-175
56. Rand JH, Wu XX, Andree HAM et al. Antiphospholipid antibodies accelerate plama coagulation by inhibiting annexin-V binding to phospholipids: a "Lupus procoagulant" phenomen. Blood 1998; 92: 1652-1660
57. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308
58. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887
59. Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects: Neuropsychological correlates and MRI findings. Stroke 1995; 26: 749-754
60. Sebastiani GD, Galeazzi M, Tincani A et al. HLA-DPBI alleles association of anticardiolipin and anti-beta 2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2003; 12: 560-563
61. Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, Vilardell-Tarres M. IgA anticardiolipin antibodies - relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998; 79: 282-285
62. Shah NM, Khamashta MA, Atsumni T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7: 3-6
63. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-236
64. Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-442
65. Sugi T, Katsunuma J, Izumi S, McIntyre JA, Makino T. Prevalence and heterogenity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999; 71: 1060-1065
66. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-529
67. Tsapanos V, Kanellopoulos N et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman. Arch Gynecol Obstet 2000; 263: 111-115
68. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311
69. Wisbey HL, Klestov AC. Thrombocytopenia corrected by warfarin in antiphospholipid syndrome. J Rheum 1996; 23: 769-771
70. Ziporen L, Shoenfeld Y et al. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. J Clin Invest 1997; 100: 613-619